Home Search
alladapt - search results
If you're not happy with the results, please do another search
FDA Fast Tracks Alladapt’s ADP101 for the Treatment of Single and Multiple Food Allergies
Fast Track Designation accelerates ADP101's development path for the treatment of food allergies.
Alladapt’s Multi-Allergen OIT Candidate Shows Promise in Clinical Study
Company will begin Phase 3 study in 2024.
Alladapt Announces Positive Results for Multi-Allergen OIT Candidate from Phase 1/2 Trial
OIT candidate treats allergies to the Top 9 allergens at the same time.
Alladapt’s 15-Allergen OIT Candidate Ready to Begin Phase 1/2 Study
ADP101 is intended to treat patients with an allergy to one or more of peanut, almond, hazelnut, cashew, pistachio, pecan, walnut, milk, egg, cod, salmon, shrimp, wheat, soy, and sesame.
Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat Allergies to All...
The study is still seeking participants 4-55 years of age.
Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy...
Company is developing therapy to target a number of food allergies simultaneously.
USF Begins Recruitment for OIT Study Addressing 15 Food Allergies at Once
Therapy will treat allergies to peanuts, almonds, cashew, hazelnuts, pecans, pistachios, walnuts, codfish, salmon, shrimp, sesame seed, soy, wheat, milk and eggs simultaneously.
Broad Spectrum OIT Candidate for Multiple Food Allergies Begins Phase 1/2 Clinical Trials
The Harmony Study plans to enroll patients across 20 sites in the United States.
How Much Peanut Does it Take to Trigger an Allergic Reaction?
UC toxicologist says finding an ‘eliciting dose’ may help some who have food allergies.